Did You Know?

Editor’s Picks

Latest News

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences...

Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...

error: Content is protected !!